

Dr.ssa Oriana Nanni

- Maturità Scientifica,
- Laureata in Scienze Statistiche ed Economiche presso l'Università di Bologna, (votazione 110/110).
- Specializzata in Statistica Sanitaria presso l'Università di Milano, (votazione 70/70 e lode).
- Master in Promozione e Governo della ricerca sanitaria Università di Modena e Reggio Emilia
- Responsabile statistico presso l'Unità di Biostatistica dell'Istituto Oncologico Romagnolo dal 1988 al 2007.
- Direttore dell'Unità di Biostatistica e Sperimentazioni Cliniche dell'IRST dal 2007 a tutt'oggi
- Dal 1994 svolge attività didattica presso la Scuola di specializzazione in Oncologia dell'Università di Ferrara
- Dal 1996 al 2007 è componente del Comitato Medico Scientifico dell'Istituto Oncologico Romagnolo.
- Dal 1999 –al 2007: è componente del Comitato Etico dell'Azienda USL di Forlì.
- Dal 2007 è componente del Comitato Medico Scientifico dell'IRST
- E' componente del comitato scientifico di alcuni gruppi italiani che si occupano di ricerca nel campo dell'oncologia e delle cure palliative
- Dal 2010 è componente del Comitato Etico di Modena
- Dal 2010 è componente del Comitato Etico di Area Vasta Romagna e IREST
- Dal 2011 è componente del Comitato Budget
- Dal 2 ottobre 2012 è componente della Segreteria Operativa di Sede della Commissione Terapeutica di Area Vasta Romagna
- Dal giugno 2012 è componente del Comitato Scientifico AAA-IRST
- Nel 2012 ha conseguito l' Abilitazione Scientifica Nazionale seconda fascia settore 06/M1

- E' responsabile statistico di molti studi monocentrici e multicentrici sperimentali di fase II e III ed osservazionali di ricerca biologica, clinica, epidemiologica, organizzativa, e in cure palliative.
- Ha gestito come centro coordinatore diversi studi clinici monocentrici e multicentrici secondo le Good Clinical Practice di fase II e III in ambito oncologico e in altre discipline mediche e chirurgiche.
- Ha partecipato in qualità di docente e/o esercitatore a diversi corsi-seminari-master in statistica medica, epidemiologia, oncologia.
- E'/E' stato componente di diverse società scientifiche.
- E' primo autore o co-autore di oltre 150 pubblicazioni in campo oncologico, epidemiologico e in altre discipline mediche e chirurgiche edite su riviste scientifiche internazionali

Pubblicazioni al 3/5/2015

1. D. Amadori, L. Frassinetti, A. Riccobon, A. Volpi, M. Vasini, O. Nanni, W. Zoli, G. Pallotti. Cytosol CEA: a prognosis factor in breast carcinoma? (personal experience with 76 cases). J Nucl Med Allied Sci 34(4):25-26, 1990.
2. D. Amadori, L. Frassinetti, A. Riccobon, A. Volpi, M. Vasini, O. Nanni, W. Zoli, G. Pallotti. Cytosol CEA: a prognosis factor in breast carcinoma? (personal experience with 76 cases). J Nucl Med Allied Sci. 34:25-6,1990.
3. D. Amadori, C. Bonaguri, O. Nanni, P.Gentilini, N. Lundi, W. Zoli, A. Riccobon, A. Vio, E. Magni and A..Saragoni. Cell kinetics and hormonal factors in relation to pathological stage in breast cancer. Breast Cancer Research and Treatment 18:19-25, 1991.
4. G. Rosti, O. Nanni, E. Soresi, A. Passalacqua, A. Veronesi, L. Crinò, A. Paccagnella and M. Marangolo. Long Term Survival (LTS) in Small Cell Lung Cancer (SCLC): the Italian experience. Cancer Therapy and Control 2:127-133, 1991.
5. D. Amadori, G.L. Frassinetti, E. Flamini, F. Falcini, M. Maltoni, O. Nanni, A. Riccobon and C. Piccinini. Clinical and laboratory evaluation of the myeloprotective effect of Medroxyprogesterone Acetate in head and neck cancer. Eur J Cancer 28A(8/9):1331-1334, 1992.
6. S. Ferro, A. Caroli, O. Nanni, A. Biggeri and A. Gambi. A cross selectional survey on breast self examination practice, utilization of breast professional examination, mammography and associated factors in Romagna, Italy. Tumori 78:98-105, 1992.

7. S. Savini, W. Zoli, O. Nanni, A. Volpi, G. L. Frassinetti, E. Magni, A. Flamigni, A. Amadori and D. Amadori. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. *Breast Cancer Research and Treatment* 24:27-34, 1992.
8. S. Ricca Rosellini, V. Arienti, O. Nanni, F. Ugenti, M. Tassinari, C. Camporesi, L. Boriani, G. Versari, P. L. Costa, D. Amadori, F. Miglio and G. Gasbarrini. Hepatocellular carcinoma. Prognostic factors and survival analysis in 135 Italian patients. *Journal of Hepatology* 16:66-72, 1992.
9. A. Saragoni, L. Medri, F. Bacci, F. Padovani, E. Sabattini, O. Nanni, M. Gaudio. Valore della tecnica di ibridizzazione in situ nella diagnosi delle infezioni da papilloma virus umano della cervice uterina. *Pathologica* 84:57-66, 1992.
10. D. Amadori, C. Bonaguri, A. Volpi, O. Nanni, W. Zoli, N. Lundi, A. Amadori, E. Magni and A. Saragoni. Cell kinetics and prognosis in gastric cancer. *Cancer* 71(1):1-4, 1993.
11. O. Nanni, M. Ricci, C. Lugaresi, D. Amadori, F. Falcini, E. Buiatti. Iterative use of a priori exposure matrices to improve the characterization of chemical exposures in agricultural work studies. *Scand J Work Environ Health* 19:191-9, 1993.
12. S. Franceschi, E. Negri, S. Salvini, A. Decarli, M. Ferraroni, R. Filiberti, A. Giacosa, R. Talamini, O. Nanni, G. Panarello and C. La Vecchia. Reproducibility of an Italian food frequency questionnaire for cancer studies: results for specific food items. *Eur J Cancer* 29A:1-10, 1993.
13. D. Amadori, A. Volpi, A. Callea, L. Amaducci, S. Morgagni, E. Magni and O. Nanni. Clinical relevance of cell kinetics in breast cancer. *Breast Cancer: from Biology to Therapy. Annals of the New York Academy of Sciences* 698:186-192, 1993.
14. E. Marubini, G. Bonfanti, F. Bozzetti, P. Boracchi, D. Amadori, S. Folli, O. Nanni and L. Gennari. A prognostic score for patients resected for gastric cancer. *Eur J Cancer* 29A(6):845-850, 1993.
15. L. Gianni, M. Amadori, G. Rosti, P. Rinaldi, O. Nanni, E. Pini, L. Albertazzi, E. Pasquini, P.P. Fattori, F. Desiderio, A. Tononi, A. Ravaioli. I linfomi primitivi dello stomaco. I: Storia naturale, problemi diagnostici, strategia terapeutica. *Argomenti di Oncologia* 14:283-298, 1993.
16. E. Pasquini, M. Nicolini, G. Rosti, M. Amadori, S. Pileri, O. Nanni, P. P. Fattori, M. Marangolo, D. Amadori and A. Ravaioli. Prognostic factors and survival in Non-Hodgkin's Lymphomas: the experience of the Istituto Oncologico Romagnolo (IOR). *Leukemia and Lymphoma* 14:475-482, 1994.

17. G. L. Frassinetti, O. Nanni, A. Lombardi, C. Milandri, M. Ferrari, A. De Matteis, G. Mustacchi, S. Cariello., V. Mascia, A. Santoro and D. Amadori. Lonidamine in modulation of response to adriamycin in advanced breast cancer. Preliminary results. *International Journal of Oncology* 4:741-746, 1994.
18. E. Negri, S. Franceschi, C. La Vecchia, R. Filiberti, S. Guarneri, O. Nanni, A. Decarli. The application of different correlation coefficients to assess the reproducibility of a food frequency questionnaire. *European Journal of Cancer Prevention* 3:489-497, 1994.
19. L. Bucci, M. Serafini, O. Nanni, G. Buzzi, N. Morini, C. Naldoni and P. Schincaglia. Self-selection for mammography and breast cancer incidence by stage. *Tumori* 80:118-123, 1994.
20. M. Maltoni, O. Nanni, S. Derni, M.P. Innocenti, L. Fabbri, N. Riva, R. Maltoni and D. Amadori. Clinical Prediction of Survival is more accurate than the Karnofsky Performance Status in estimating life span of terminally ill cancer patients. *European Journal of Cancer* 30A(6):764-766, 1994.
21. M. Maltoni, M. Pirovano, O. Nanni, R. Labianca and D. Amadori. Prognostic factors in terminal cancer patients. *European Journal of Palliative Care* 1(3):122-125, 1994.
22. G. Rosti, M. L. Meacci, O. Nanni, L. Albertazzi, F. Zumaglini, B. Vertogen and M. Marangolo. Do Italian Small Cell Lung Cancer (SCLC) specialists share a common language? An analysis on 549 questionnaires. *Anticancer Research* 14:305-308, 1994.
23. M. Maltoni, A. Volpi, O. Nanni, E. Magni, G.N. Ranzani, M. Gaudio and D. Amadori. Oncogene amplification and proliferative activity in gastric cancer: new prognostic factors? 1st International Gastric Cancer Congress, Kyoto (Japan) 29 March-1 April 1995, pp. 767-771.
24. U. Baldari, A. Monti, A. Callea, O. Nanni. How, who, when and where does basal cell carcinoma begin to affect people? A report of 595 patients. *Chronica Dermatologica* 1:113-126, Gennaio-Febbraio 1995.
25. D. Amadori, O. Nanni, M. Ricci, F. Falcini, A. Decarli, D. Palli and E. Buiatti. Hospital versus population controls in a retrospective study on diet and stomach cancer. *European Journal of Public Health* 5:209-214, 1995.
26. D. Amadori, O. Nanni, F. Falcini, A. Saragoni, V. Tison, A. Callea, E. Scarpi, M. Ricci, N. Riva, E. Buiatti. Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on job titles. *Occup Environ Med* 52:374-379, 1995.
27. S. Folli, M. Dente, D. Dell'Amore, M. Gaudio, O. Nanni, L. Saragoni and A. Vio. Early gastric cancer: prognostic factors in 223 patients. *British Journal of Surgery* 82:952-956, 1995.

28. M. Maltoni, M. Pirovano, E. Scarpi, M. Marinari, M. Indelli, E. Arnoldi, M. Gallucci, L. Frontini, L. Piva and D. Amadori. Prediction of survival of patients terminally ill with cancer. Co-authorship: O. Nanni, et al. Cancer 75(10):2613-2622, 1995 anche "Year Book of Oncology"-Mosby-Year Book, Inc.1995.
29. S. Franceschi, F. Barbone, E. Negri, A. Decarli, M. Ferraroni, R. Filiberti, A. Giacosa, P. Gnagnarella, O. Nanni, S. Salvini, C. La Vecchia. Reproducibility of an Italian food frequency questionnaire for cancer studies: results for specific nutrients. Ann Epidemiol 5:69-75, 1995.
30. A. Tavani, E. Negri, M. Ferraroni, B. D'Avanzo, A. Decarli, A. Giacosa, C. La Vecchia, O. Nanni, M.T. Parpinel, S. Salvini, R. Talamini, S. Franceschi. Influence of some covariates on the reproducibility of an Italian semi-quantitative food frequency questionnaire. Eur J Cancer Prev 4:319-327, 1995.
31. A. Saragoni, M. Gaudio, F. Padovani, L. Medri, F. Bacci, L. Saragoni, S. Folli, O. Nanni. Il carcinoma gastrico in fase iniziale: follow-up di 221 pazienti. Studio clinico-patologico dei fattori che influenzano la prognosi. Acta Oncologica 4:321-327, 1995.
32. M.T. Parpinel, P. Gnagnarella, S. Salvini, M. Ferraroni, E. Negri, R. Filiberti, O. Nanni, S. Franceschi. Riproducibilità di un questionario alimentare per lo studio della relazione tra dieta e tumori. Giornale Italiano di Nutrizione Clinica e Prev 4:7-21, 1995.
33. L. Bucchini, M. Serafini, G. Rosti, F. Zumaglini and O. Nanni. Patterns of Gastric Cancer Care by Age. A Registry-based Study in Romagna. Eur J Cancer 31:1548-9, 1995.
34. G. Masala, S. Di Lollo, C. Picoco, P. Crosignani, V. Demicheli, A. Fontana, I. Funto, L. Miligi, O. Nanni, A. Papucci, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Vigano, C. Vindigni, A. Seniori Costantini, P. Vineis. Incidence rates of leukemias, lymphomas and myelomas in Italy: geographic distribution and NHL histotypes. Int J Cancer. 68(2):156-9, 1996.
35. P. Vineis and the Working Group on the Epidemiology of Hematolymphopoietic Malignancies in Italy (O. Nanni et al.). Incidence and time trends for lymphomas, leukemias and myelomas: hypothesis generation. Leukemia Research 20:285-290, 1996.
36. C. La Vecchia, E. Negri, S. Franceschi, A. Favero, O. Nanni, R. Filiberti, E. Conti, M. Montella, A. Veronesi, M. Ferraroni, A. Decarli. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Ca 72:244-248, 1995.
37. M. Maltoni, E. Sansoni, S. Derni, C. Milandri, F. Martini, O. Nanni, L. Fabbri and D. Amadori. Topical prostaglandin E2 and chemo- and radio-induced oral mucositis: Report on 15 cases. Oncology Reports 3:205-208, 1996.

38. B. D'Avanzo, O. Nanni, C. La Vecchia, S. Franceschi, E. Negri, A. Giacosa, E. Conti, M. Montella, R. Talamini and A. Decarli. Physical Activity and Breast Cancer Risk. *Cancer Epidemiol, Biomarkers Prev* 5:155-60,1996.
39. O. Nanni, D. Amadori, C. Lugaresi, F. Falcini, E. Scarpi, A. Saragoni, E. Buiatti. Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices. *Occup Environ Med* 53:652-7,1996.
40. M. Mattoni, M. Pirovano, O.Nanni. Studies Signaling the Prognostic Factors of Terminally Ill Phases. *J Pain Symptom Manage*12:205, 1996.
41. B. Renault, D. Calistri, G. Buonsanti, O. Nanni, D. Amadori, G.N. Ranzani. Microsatellite instability and mutations of p53 and TGF- β RII genes in gastric cancer. *Hum Genet* 98:601-7, 1996
42. R. Talamini, M.T. Parpinel, S. Franceschi, C. La Vecchia, E. Negri, B. D'Avanzo, E. Conti, A. Giacosa, O. Nanni, M. Montella. Ruolo dei fattori riproduttivi e mestruali nell'eziologia del cancro della mammella in relazione all'età della diagnosi. *Epid Prev* 20:142, 1996.
43. S. Ferro, A. Caroli, O.Nanni, A. Biggeri and A. Gambi. A randomized trial on breast self-examination in Faenza (Northern-Italy). *Tumori* 82:329-34, 1996.
44. M. Maltoni, L. Fabbri, O. Nanni, E. Scarpi, L.Pezzi, E. Flamini, A. Riccobon, S. Derni, G. Pallotti, D. Amadori. Serum levels of tumor necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. *Support Care Cancer* 5:130-135, 1997.
45. D. Amadori, M. Maltoni, A. Volpi, O. Nanni, E. Scarpi, B.Renault, N.S. Pellegata, M. Gaudio, E. Magni, G. N. Ranzani, Gene Amplification and Proliferative Kinetics in Relation to Prognosis of Patients with Gastric Carcinoma. *Cancer* 79: 226-232, 1997
46. M. Maltoni, M.Pirovano, O. Nanni, M. Marinari, M.Indelli, A. Gramazio, E. Terzoli, M. Luzzani, F.De Marinis, A.Caraceni, R. Labianca and the Italian multicenter study group on palliative care. Biological Indices Predictive of Survival in 519 Italian Terminally Ill Cancer Patients. *J Pain Symptom Manage* 13:1-9,1997.
47. D. Amadori, A.Volpi, R. Maltoni, O. Nanni, L. Amaducci, A. Amadori, D.Casadei Giunchi, A. Vio, A. Saragoni e R. Silvestrini. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. *Breast Cancer Res Treat* 43: 7-14,1997.

48. L. Saragoni, M. Gaudio, F. Padovani, F. Bacci, L. Medri, O. Nanni, S. Folli, A. Saragoni. Identification of occult micrometastases in patients with early gastric cancer, using anti-cytokeratins monoclonal antibody. 2nd international gastric cancer congress ,1997.
49. S. Folli, M. Dente, D. Dell'Amore, O. Nanni, E. Scarpi, M. Gaudio, L. Saragoni, A. Vio. Risk Factors for lymph node metastases in early gastric cancer. 2nd international gastric congress, 1997.
50. A. Verdecchia and the ITACARE Working Group (for CR of Romagna: F. Falcini, O. Nanni). Survival in adult Italian cancer patients, 1978-1989. Tumori 83:39-425,1997.
51. S. Franceschi, A.Favero, C. La Vecchia, E.Negri, E. Conti, M. Montella, A. Giacosa, O. Nanni, A. Decarli. Foods groups and risk of colorectal cancer in Italy. Int. J. Cancer 72:56-61,1997.
52. A. Tisselli, P. Pieri, G.Moscatelli, M.Agostini, O.Nanni, A. Spinelli, P.Riva. Prognostic value of persistent thallium-201 defects that become reversible after injection in patients with chronic myocardial infarction. J Nucl cardiol 4:195-201, 1997.
53. M. Maltoni, C. Travaglini, M. Santi, O. Nanni, E. Scarpi, S. Benvenuti, L. Albertazzi, L. Amaducci, S. Derni, L. Fabbri, A. Masi, L.Montanari, G. Pasini, A. Polselli, U. Tonelli, P. Turci, D. Amadori. Evaluation of the cost of home care for terminally ill cancer patients. Support Care Cancer 5:396-401, 1997
54. The Romagna Cancer Registry and Collaborators (O. Nanni et al.). Breast Carcinoma Stage in Relation to Time Interval since Last Mammography. A Registry-based Study. Cancer 80:1432-7, 1997.
55. L. Bucchi, A. Piatessi, F. Falcini, O. Nanni, D. Amadori. Effect of routine mammography practice on tumour size of a registry-based series of breast cancer cases compared with those observed in a screening cohort. Br J Radiol 70:1174-7,1997.
56. M.Maltoni, O. Nanni. The cost of home care hospice for terminally ill cancer patients. Topics on Supp Care 4:13-14,1997.
57. L. Saragoni, M. Gaudio, A. Vio, S.Folli, O. Nanni, A. Saragoni. Early gastric cancer in the province of Forlì: Follow-up op 337 patients in a high risk region for gastric cancer. Oncology Report 5:945-8, 1998.
58. M. Maltoni, O. Nanni, M. Naldoni, P. Serra, D. Amadori. Evaluation of cost of home therapy for patients with terminal diseases. Current Opinion in Oncology 10:302-309,1998.
59. O. Nanni, F.Falcini, E. Buiatti, L. Bucchi, M. Naldoni, P. Serra, E. Scarpi, L. Saragoni, D. Amadori. Multiple myeloma and work in agriculture: results of a case-control study in Forlì, Italy. Cancer Causes and Control 9:277-283,1998.

60. M. Maltoni, A. Volpi, O. Nanni, P. Bajorko, E. Belletti, A.M. Vecchi, M. Liverani, S. Danesi, D. Calistri, L. Ricotti and D. Amadori. Gastric cancer: epidemiologic and biological aspects. FORUM 8:199-207, 1998.
61. Registro Tumori della Romagna (O.Nanni et al), Registrazione del cancro della mammella e screening mammografico in Romagna. Epid Prev 22:94-102,1998.
62. D. Amadori, G.L. Frassinetti, A. De Matteis, G. Mustacchi, A. Santoro, S. Cariello, M. Ferrari, O. Nascimben, O. Nanni, A. Lombardi, E. Scarpi and W. Zoli. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial. Breast Cancer Res Treat 49: 209-217,1998.
63. R. Talamini, S. Franceschi, L.Dal Maso, E. Negri, E. Conti, R. Filiberti, M.Montella, O. Nanni, and C. La Vecchia. The Influence of Reproductive and Hormonal Factors on the Risk of Colon and Rectal Cancer in Women. Eur J Cancer 34:1070-6, 1998.
64. M. Pirovano, M. Maltoni, O. Nanni, M. Marinari, M. Indelli, G. Zaninetta, V. Petrella, S. Barni, E. Zecca, E. Scarpi, R. Labianca, D. Amadori, and G. Luporini for the Italian Multicenter and Study Group on Palliative Care. A new palliative Prognostic Score: A First Step for the Staging of Terminally ill Cancer Patients. J Pain Symptom Manage 17: 231-239, 1999.
65. M. Maltoni, O. Nanni, M. Pirovano, E. Scarpi, M. Indelli, C. Martini, M. Monti, E. Arnoldi, L. Piva, A. Ravaioli , G. Cruciani, R. Labianca, D. Amadori and Italian Multicenter Study Group on Palliative Care. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.J Pain Symptom Manage 17: 240-7, 1999.
66. Italian Study Group for the Di Bella Multitherapy Trials (O. Nanni et al.) Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Br Medical J 318: 224-228, 1999.
67. P. Vineis, P.Crosignani, C. Sacerdote,A. Fontana, G.Masala, L. Miligi, O. Nanni, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Viganò, C. Vindigni, and A. Seniori Costantini. Hematopoietic cancer and peptic ulcer: a multicenter case-control study. Carcinogenesis 20:1459-63, 1999.
68. P. Vineis, G. Masala, A. Seniori Costantini,and the Working Group for the Epidemiology of Hematolymphopoietic Malignancies in Italy(O. Nanni et al.). Does a gene in the Xq 28 region increase the risk of non-Hodgkin's lymphomas? Annals Oncol 10:471-3, 1999.

69. L. Miligi, A. Seniori Costantini, P. Crosignani, A. Fontana, G. Masala, O. Nanni, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Vigano, C. Vindigni, P. Vineis. Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. *Am J Ind Med.* 36(1):60-9, 1999
70. L. Medri, O. Nanni, A. Volpi, E. Scarpi, A. Dubini, A. Riccobon, A. Becciolini, S. Bianchi, D. Amadori. Tumor microvessel density and prognosis in node-negative breast cancer. *Int. J Cancer (Pred Oncol)* 89:74-80, 2000.
71. A. Volpi, O. Nanni, A. M. Vecchi, S. Naldi, L. Bernardi, L. Marri, S. Luzi Fedeli, P. Serra and D. Amadori Feasibility of a cell kinetics-based adjuvant chemotherapy trial in axillary node-negative breast cancer. *Tumori* 86: 142-8, 2000.
72. R. Fedriga, D. Calistri, O. Nanni, L. Cortesi, L. Saragoni and D. Amadori. Relation between food habits and p53 mutational spectrum in gastric cancer patients. *Int J Oncol* 17:127-33, 2000.
73. A. Volpi, F. De Paola, O. Nanni, A. M. Granato, P. Bajorko, A. Becciolini, E. Scarpi, A. Riccobon, M. Balzi, and D. Amadori. Prognostic significance of biologic markers in node - negative breast cancer patients: a prospective study. *Breast Cancer Res Treat* 63:181-92, 2000.
74. D. Amadori, O. Nanni, M. Marangolo, P. Pacini, A. Ravaioli, A. Rossi, A. Gambi, G. Catalano, D. Perroni, E. Scarpi, D. Casadei Giunchi, A. Tienghi, A. Becciolini, A. Volpi. DFS advantage of adjuvant CMF in node negative rapidly proliferating breast cancer patients: a randomised multicentre study. *J Clin Oncol* 18:3125-34, 2000 .
75. P. Vineis, P. Crosignani, C. Sacerdote, A. Fontana, G. Masala, L. Miligi, O. Nanni, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Viganò, C. Vindigni, and A. Seniori Costantini. Hematopoietic cancer and medical history: a multicentre case control study. *J Epidemiol Community Health* 54:431-6, 2000.
76. A. Caraceni, O. Nanni, M. Maltoni, L. Piva, M. Indelli, E. Arnoldi, M. Monti, L. Montanari, D. Amadori, F. de Conno. Impact of delirium on the short term prognosis of advanced cancer patients. *Cancer* 89: 1145-9, 2000.
77. A. Saragoni, L. Medri, F. Bacci, A. Dubini, M. Gaudio, F. Padovani, L. Saragoni, E. Scarpi, O. Nanni. I fattori prognostici dei carcinomi polmonari e correlazioni cliniche. *Eur J Oncol* 5:49-52, 2000.
78. P. Vineis, L. Militi, P. Crosignani, A. Fontana, G. Masala, O. Nanni, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Viganò, C. Vindigni, A. Seniori Costantini. Delayed

- infection, family size and malignant lymphomas. *J Epidemiol Community Health* 54:907-11, 2000.
79. M. Maltoni, O. Nanni, E. Scarpi, D. Rossi, P. Serra, D. Amadori. High dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. *Ann Oncol* 12:289-300, 2001.
 80. E. Stagnaro, V. Ramazzotti, P. Crosignani, A. Fontana, G. Masala, L. Miligi, O. Nanni, M. Neri, S. Rodella, A. Seniori Costantini, R. Tumino, C. Viganò, C. Vindigni, P. Vineis. Smoking and hematolymphopoietic malignancies. *Cancer Causes Control* 12:325-34, 2001.
 81. E. Scarpi, F. De Paola, M. Sarti, P. Bajorko, AM. Granato, A. Volpi, O. Nanni, R. Maltoni, D. Amadori. Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. *Breast Cancer Res Treat* 68:101-10, 2001
 82. S. Folli, P. Morgagni, F. Roviello, G. De Manzoni, D. Marrelli, L. Saragoni, A. Di Leo, M. Gaudio, O. Nanni, A. Carli, C. Cordiano, D. Dell'Amore, A. Vio. Risk factors for Lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). *Jpn J Clin Oncol* 31:495-9, 2001.
 83. R. Fedriga, R. Gunelli, O. Nanni, F. Bacci, D. Amadori, D. Calistri. Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. *Neoplasia* 3:446-50, 2001.
 84. P. Vineis, P. Crosignani, P. Viganò, A. Fontana, G. Masala, L. Miligi, AS Costantini, O. Nanni, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Vindigni, and A. Seniori Costantini. Lymphomas and multiple sclerosis in a multicenter case-control study. *Epidemiology* 12: 134-5, 2001.
 85. R. Ridolfi, V. Chiarion Sileni, M. Guida, A. Romanini, R. Labianca, A. Freschi, G. Lo Re, R. Nortilli, S. Brugnara, P. Vitali, O. Nanni for the Italian Melanoma Intergroup (IMI). Cisplatin, Dacarbazine, with or without subcutaneous Interleukin-2, and Interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. *J Clin Oncol* 20:1600-7, 2002.
 86. O. Nanni, G. Zoffoli, E. Scarpi, L. Bucchi, P. Lauriola, C. Cislighi, D. Amadori. Gastric cancer mortality in the spouses of patients who died from gastric cancer. *Int. J Epidemiol* 31:468-472, 2002.
 87. E. Scarpi, F. De Paola, M. Sarti, A. M. Granato, A. Volpi, O. Nanni, R. Maltoni, D. Amadori. Rilevanza clinica di marcatori biologici in pazienti con carcinoma mammario operabile, trattati con tamoxifene adiuvante. *Trends in Medicine* 3:175-181, 2002.

88. G. Favalli, P.F. Conte, D. Kastaros, P. Zola, O. Nanni, A. Gadducci, L. Amadori S. Pecorelli. Randomized Phase III Trial of observation versus 6 courses of single agent paclitaxel in patients with advanced ovarian cancer who attained a complete response to platinum-paclitaxel based chemotherapy. An italian study (AFTER-6 protocol 1). 9th biennial meeting of the Int. Gynecologic Cancer Society, 2002.
89. R. Ridolfi, O. Nanni. In Reply to: Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b an advanced melanoma outpatients. J Clin. Oncol. 20:3560-3561, 2002.
90. L. Riccioni, P. Farabegoli, O. Nanni, F. Morigi , M. Polverelli , G. Landi, F. Giangaspero. The sentinel lymph node in melanoma: utilization of molecular biology (RT-PCR) to detect occult metastases. Pathologica. 94(4):190-5, 2002
91. O. Nanni, A. Volpi, G. L. Frassinetti, F. De Paola, A. M. Granato, A. Dubini, W zoli, E. Scarpi, D. Turci, G. Oliverio, A. Gambi, D. Amadori. Role of biological markers in the clinical outcome of colon cancer. Brit J Cancer 87:868-875, 2002.
92. GL. Frassinetti, T. Ibrahim, W. Zoli, M. Monti, L. Ricotti, O. Nanni, D. Amadori. Docetaxel followed by Gemcitabine in the treatment of advanced non-small cell lung cancer: a phase I study. Tumori, 88: 99-103, 2002
93. P. Vineis, L. Miligi, P. Crosignani, L. Davico, A. Fontana, G. Masala, O. Nanni, V. Ramazzotti, S. Rodella, E. Stagnaro, R. Tumino, C. Viganò, AS Costantini. Delayed infection, late tonsillectomy or adenoidectomy and adult leukemia: a case control study. Br J Cancer 13:47-49, 2003.
94. C. Dazzi , A. Cariello, P. Giovanis , M. Monti, B. Vertogen, M. Leoni, A. Tienghi, D. Turci, G. Rosti, O. Nanni, C. Rondoni, M Marangolo. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol. 14(4):559-63, 2003.
95. A. Volpi, O. Nanni, F. De Paola, AM . Granato, A. Mangia, F. Monti, F. Schitulli, M. De Lena, E. Scarpi, P. Rosetti, M. Monti, L. Gianni, D. Amadori, A. Paradiso. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 21 (14) 2708-12, 2003.
96. L. Medri, A. Volpi, O. Nanni, AM Vecchi, A. Mangia, F. Schittulli, F. Padovani, D. Casadei Giunchi, A. Vito, D. Amadori, A. Paradiso, R. Silvestrini. Prognostic relevance of mitotic

- activity in patients with node-negative breast cancer. *Mod Pathol.* 16(11):1067-75, 2003.
97. L. Miligi, AS. Costantini, V. Bolejack, A. Veraldi, A. Benvenuti, O. Nanni, V. Ramazzotti, R. Tumino, E. Stagnaro, S. Rodella, A. Fontana, C. Vindigni, P. Vineis. Non-Hodgkin's lymphoma, leukemia, and exposures in agriculture: results from the Italian multicenter case-control study. *Am J Ind Med.* 44(6):627-36, 2003.
 98. M. Guida, A. Ravaioli, VC Sileni, A. Romanini, R. Labianca, A. Freschi, S. Brugnara, A. Casamassima, V. Lorusso, O. Nanni, R. Ridolfi. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. *J Transl Med.* 22;1(1):13, 2003.
 99. V. Chiarion Sileni, P. Del Bianco, GL. De Salvo, G. Lo Re, A. Romanini, R. Labianca, R. Nortilli, E. Corgna, M. dalla Palma, G. Lo Presti, R. Ridolfi on the behalf of IMI (O. Nanni et al). Qualità of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. *Eur J Cancer.* 39:1577-85, 2003.
 100. F. Di Costanzo, A. Sombrero, S. Gasperoni, L. Dogliotti, L. Frassineti, A. Falcone, R. Lionetto, P. Bruzzi, G. Luppi, L. Gallo, P. Conte, A. Comandone, D. Turci, M. Marzola, U. Folco, E. Pfanner, M. Mestriner, C. Boni, C. Galli, M. Tonato, R. Rosso, on behalf of INTACC (O.Nanni et al). Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon cancer (INTACC). *Ann Oncol.*,14:1365-72, 2003
 101. AM. Granato, O. Nanni, F. Falcini, S. Folli, G. Mosconi, F. De Paola, L. Medri, D. Amadori, A. Volpi. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? *Breast Cancer Res.* 6(1):R38-45, 2004.
 102. E. Stagnaro, R. Tumino, S. Parodi, P. Crosignani, A. Fontana, G. Masala, L. Miligi, O. Nanni, V. Ramazzotti, S. Rodella, A. Seniori Constantini, C. Vigano, C. Vindigni, P. Vineis. Non-Hodgkin's lymphoma and type of tobacco smoke. *Cancer Epidemiol Biomarkers Prev.* 13(3):431-7, 2004.
 103. L. Bucci, O. Nanni, A. Ravaioli, F. Falcini, R. Ricci, E. Buiatti, D. Amadori. Cancer mortality in a cohort of male agricultural workers from northern Italy. *J Occup Environ Med.* 46(3):249-56, 2004.
 104. MA. Sanchini, S. Bravaccini, L. Medri, R. Gunelli, O. Nanni, F. Monti, PC. Baccarani, A. Ravaioli, E. Bercovich, D. Amadori, D. Calistri. Urine telomerase: an important marker in the diagnosis of bladder cancer. *Neoplasia.* 6(3):234-9, 2004.

105. U. De Giorni, G. Papiani, S. Zago, G. Lanzaova, M. Ballardini, O. Nanni, M. Marangolo, G. Rosti. Extragonadal germ cell tumors. Tumori.3(2):45-48, 2004.
106. D. Calistri, C. Rengucci, A. Lattuneddu, G. Francioni, AM. Polifemo, O. Nanni, L. Saragoni, F. Monti, A. Ravaioli, W. Zoli, D. Amadori. Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia. 6(5):536-40, 2004.
107. MA. Sanchini, R. Gunelli, O. Nanni, S. Bravaccini, C. Fabbri, A. Sermasi, E. Bercovich, A. Ravaioli, D. Amadori, D. Calistri. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 294(16):2052-6, 2005
108. O. Nanni, A. Ravaioli, L. Bucchi, F. Falcini, R. Ricci, E. Buiatti, D. Amadori. Relative and absolute cancer mortality of women in agriculture in northern Italy. Eur J Cancer Prev. 14(4):337-44, 2005.
109. M. Maltoni, E. Scarpi, C. Modonesi, A. Passardi, S. Calpona, A. Turriziani, R. Speranza, D. Tassinari, P. Magnani, D. Saccani, L. Montanari, B. Roudnas, D. Amadori, L. Fabbri, O. Nanni, P. Raulli, B. Poggi, F. Fochessati, D. Giannunzio, ML. Barbagallo, V. Minnotti, M. Betti, S. Giordani, E. Piazza, R. Scapaticci, S. Ferrario. A validation study of the WHO analgesic ladder: a two-step vs three-2005step strategy. Support Care Cancer. 13(11):888-94, 2005
110. M. Guida, A. Riccobon, G. Biasco, A. Ravaioli, A. Casamassima, A. Freschi, MD. Palma, E. Galligioni, R. Nortilli, V. Chiarion-Sileni, J. Picozzo, A. Romanini, O. Nanni, R. Ridolfi on behalf of Italian Melanoma Intergroup (IMI). Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res. 16(4):317-323, 2006.
111. T. Battaglioli, G. Gorini, AS. Costantini, P. Crosignani, L. Miligi, O. Nanni, E. Stagnaro, R. Tumino, P. Vineis. Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin's lymphoma: a population-based study. Ann Oncol. 17(8):1283-9, 2006.
112. A. Passardi, I. Massa, W. Zoli, L. Gianni, C. Milandri, F. Zumaglini, O. Nanni, R. Maltoni, GL. Frassinetti, D. Amadori. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer. 21;6:76, 2006.
113. A. Gennari, D. Amadori, M. De Lena, O. Nanni, P. Bruzzi, V. Lorusso, L. Manzione, PF. Conte. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic

- breast cancer. *J Clin Oncol.* 24(24):3912-8, 2006.
114. AM. Granato, GL. Frassineti, N. Giovannini, M. Ballardini, O. Nanni, R. Maltoni, D. Amadori, A. Volpi. Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer? *Tumour Biol.* 27(6):302-308, 2006.
 115. E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, GM. Verdecchia, D. Amadori. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. *Clin Cancer Res.* 12(23):6985-8, 2006
 116. G. Gorini, E. Stagnaro, V. Fontana, L. Miligi V. Ramazzotti, O. Nanni, S. Rodella, R. Tomino, P. Crosignani, C. Vindigni, A. Fontana, P. Vineis, AS. Costantini. Alcohol consumption and risk of leukemia: A multicenter case-control study. *Leuk Res.* 31(3):379-86, 2007.
 117. S. Bravaccini, MA. Sanchini, AM. Granato, R. Gunelli, O. Nanni, D. Amadori, D. Calistri, R. Silvestrini. Urine telomerase activity for the detection of bladder cancer in females. *J Urol.* 178(1):57-61, 2007.
 118. R. Gunelli, E. Bercovich, O. Nanni, M. Ballardini, GL Frassineti N. Giovannini, M. Fiori, E. Pasquini, P. Ulivi, GL. Pappagallo, R. Silvestrini, W. Zoli. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. *Br J Cancer.* 97(11):1499-504, 2007.
 119. A. Passardi, R. Maltoni, C. Milandri, L. Cecconetto, I. Massa, W. Zoli, A. Tesei, F. Fabbri, O. Nanni, D. Amadori. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies. *Oncology.* 72(1-2):118-24, 2007.
 120. D. Amadori, O. Nanni, A. Volpi, D. Casadei Giunchi, M. Marangolo, L. Livi, A. Ravaioli, AP. Rossi, A. Gambi, S. Luzi Fedeli, D. Perroni, E. Scarpi, A. Becciolini, R. Silvestrini. Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. *Breast Cancer Res Treat.* 108(2):259-64, 2008.
 121. G. Lelli, S. Cataldo, I. Carandina, B. Urbini, F. Bonetti, M. Marzola, G. Biasco, MA Pantaleo, A. Brandes, C. Calandri, E. Ravaioli, O. Nanni, C. Boni, C. Banzi, F. Negri, A. Panetta, F. Di Fabio, D. Turci. The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice. *J Chemother.* 20(3):374-9, 2008.

122. A.Passardi, L. Cecconetto, M. Dall'agata, C. Dazzi, E. Pasquini, G. Oliverio, F. Zumaglini, W. Zoli, O. Nanni, C. Milandri, GL. Frassinetti, D. Amadori. Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer. *J Transl Med.* 6:65, 2008 .
123. Casadio V, Bravaccini S, Gunelli R, Nanni O, Zoli W, Amadori D, Calistri D, Silvestrini R. Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. *Int J Biol Markers.* 2009 Oct-Dec;24(4):253-7.
124. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. *J Clin Oncol.* 2009 Oct 1;27(28):4642-8.
125. Maltoni M, Pittureri C, Scarpi E, Piccinini L, Martini F, Turci P, Montanari L, Nanni O, Amadori D. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. *Ann Oncol.* 2009 Jul;20(7):1163-9.
126. Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Cecconetto L, Sarti S, Pietri E, Nanni O, Amadori D. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer. *Cancer Chemother Pharmacol.* 2010 Apr;65(5):871-6.
127. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D'Amico M, DeCensi A, Bruzzi P. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. *J Clin Oncol.* 2011 Jun 1;29(16):2144-9.
128. Gurioli C, Ravaglia C, Romagnoli M, Casoni G, Tomassetti S, Nanni O, Poletti V. EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series. *Clin Respir J.* 2011 Apr 11. doi: 10.1111/j.1752-699X.2010.00232.x.
129. Amadori D, Milandri C, Comella G, Saracchini S, Salvagni S, Barone C, Bordonaro R, Gebbia V, Barbato A, Serra P, Gattuso D, Nanni O, Baconnet B, Gasparini G. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. *Eur J Cancer.* 2011 Jun 10. [Epub ahead of print] PubMed PMID: 21665463.
130. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, Dorni

- S, Fabbri L, Rosati M, Amadori D, Nanni O. Prospective comparison of prognostic scores in palliative care cancer populations. *Oncologist*. 2012;17(3):446-54. doi: 10.1634/theoncologist.2011-0397. Epub 2012 Feb 29. PubMed PMID: 22379068; PubMed Central PMCID: PMC3316931
131. Scarpi E, Maltoni M, Miceli R, Mariani L, Caraceni A, Amadori D, Nanni O. Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. *Oncologist*. 2011;16(12):1793-9. doi: 10.1634/theoncologist.2011-0130. Epub 2011 Oct 31. PubMed PMID: 22042788; PubMed Central PMCID: PMC3248779.
132. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, Derni S, Fabbri L, Rosati M, Amadori D, Nanni O. Prospective comparison of prognostic scores in palliative care cancer populations. *Oncologist*. 2012;17(3):446-54. doi: 10.1634/theoncologist.2011-0397. Epub 2012 Feb 29. PubMed PMID: 22379068; PubMed Central PMCID: PMC3316931.
133. Maltoni M, Scarpi E, Rosati M, Derni S, Fabbri L, Martini F, Amadori D, Nanni O. Palliative sedation in end-of-life care and survival: a systematic review. *J-Clin Oncol*. 2012 Apr 20;30(12):1378-83. doi: 10.1200/JCO.2011.37.3795. Epub 2012 Mar 12. Review. Erratum in: *J Clin Oncol*. 2012 Sep 20;30(27):3429. PubMed PMID: 22412129.
134. Tomassetti S, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciucchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. Transbronchial biopsy is useful in predicting UIP pattern. *Respir Res*. 2012 Oct 29;13:96. doi: 10.1186/1465-9921-13-96. PubMed PMID: 23107232; PubMed Central PMCID: PMC3499172.
135. Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. *Oncology*. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19. PubMed PMID: 23257904.
136. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassinetti GL, Amadori D, Rocca A. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. *Heart*.

- 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151. Epub 2013 Jan 24. PubMed PMID: 23349345.
137. Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, Bodei L, Garaboldi L, Bartolomei M, Paganelli G. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. *Neuroendocrinology*. 2013;97(4):347-54. doi: 10.1159/000348394. Epub 2013 May 22. PubMed PMID: 23392072.
 138. Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L, Paganelli G. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2013 Jun;40(6):881-8. doi: 10.1007/s00259-013-2369-z. Epub 2013 Feb 27. PubMed PMID: 23443937.
 139. Parodi S, Crosignani P, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Tumino R, Vindigni C, Vineis P, Stagnaro E. Childhood infectious diseases and risk of leukaemia in an adult population. *Int J Cancer*. 2013 Oct 15;133(8):1892-9. doi: 10.1002/ijc.28205. Epub 2013 Jul 6. PubMed PMID: 23575988.
 140. Maltoni M, Scarpi E, Nanni O. Palliative sedation in end-of-life care. *Curr Opin Oncol*. 2013 Jul;25(4):360-7. doi: 10.1097/CCO.0b013e3283622c47. Review. PubMed PMID: 23666472.
 141. Buggi F, Mingozzi M, Curcio A, Rossi C, Nanni O, Bedei L, Sanna PA, Veltri S, Folli S. Intra-operative radiological margins assessment in conservative treatment for non-palpable DCIS: correlation to pathological examination and re-excision rate. *Springerplus*. 2013 May 24;2(1):243. doi: 10.1186/2193-1801-2-243. Print 2013 Dec. PubMed PMID: 23741658; PubMed Central PMCID: PMC3669500.
 142. Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. *Cancer Epidemiol Biomarkers Prev*. 2013 Oct;22(10):1862-7. doi: 10.1158/1055-9965.EPI-13-0595. Epub 2013 Aug 14. PubMed PMID: 23945199.
 143. Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial?--Authors' reply. *Lancet Oncol*. 2013 Sep;14(10):e388-90. doi: 10.1016/S1470-2045(13)70295-X. PubMed PMID: 3993381.

144. Corso RM, Petrini F, Buccioli M, Nanni O, Carretta E, Trollo A, De Nuzzo D, Pigna A, Di Giacinto I, Agnoletti V, Gambale G. Clinical utility of preoperative screening with STOP-Bang questionnaire in elective surgery. *Minerva Anesthesiol.* 2014 Aug;80(8):877-84. Epub 2013 Nov 26. PubMed PMID: 24280812.
145. Masini C, Nanni O, Antaridi S, Gallegati D, Marri M, Paolucci D, Minguzzi M, Altini M. Automated preparation of chemotherapy: quality improvement and economic sustainability. *Am J Health Syst Pharm.* 2014 Apr 1;71(7):579-85. doi: 10.2146/ajhp130489. PubMed PMID: 24644118.
146. Amadori D, Serra P, Bravaccini S, Farolfi A, Puccetti M, Carretta E, Medri L, Nanni O, Tumedei MM, Kahima J, Masalu N. Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations. *Breast Cancer Res Treat.* 2014 May;145(1):177-83. PubMed PMID: 24658893.
147. Altini M, Carretta E, Morgagni P, Carradori T, Ciotti E, Prati E, Garcea D, Amadori D, Falcini F, Nanni O. Erratum to: Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients. *Gastric Cancer.* 2015 Jan;18(1):167. doi: 10.1007/s10120-014-0373-z. PubMed PMID: 24760337.
148. Maltoni M, Scarpi E, Nanni O. Palliative sedation for intolerable suffering. *Curr Opin Oncol.* 2014 Jul;26(4):389-94. doi: 10.1097/CCO.0000000000000097. Review. PubMed PMID: 24825017.
149. de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN- α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. *J Transl Med.* 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209. PubMed PMID: 25053129; PubMed Central PMCID: PMC4223722.
150. Farolfi A, Della Luna C, Ragazzini A, Carretta E, Gentili N, Casadei C, Aquilina M, Barone D, Minguzzi M, Amadori D, Nanni O, Gavelli G. Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients. *Oncologist.* 2014 Aug;19(8):823-8. doi: 10.1634/theoncologist.2013-0470. Epub 2014 Jul 25. PubMed PMID: 25063226; PubMed Central PMCID: PMC4122472.

151. Moja L, Liberati EG, Galuppo L, Gorli M, Maraldi M, Nanni O, Rigon G, Ruggieri P, Ruggiero F, Scaratti G, Vaona A, Kwag KH. Barriers and facilitators to the uptake of computerized clinical decision support systems in specialty hospitals: protocol for a qualitative cross-sectional study. *Implement Sci.* 2014 Aug 28;9:105. doi: 10.1186/s13012-014-0105-0. PubMed PMID: 25163794; PubMed Central PMCID: PMC4159504
152. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjosé S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadié M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Krickler A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014 Aug;2014(48):130-44. doi: 10.1093/jncimonographs/lgu013. PubMed PMID: 25174034; PubMed Central PMCID: PMC4155467.
153. Scarpi E, Calistri D, Klepstad P, Kaasa S, Skorpen F, Habberstad R, Nanni O, Amadori D, Maltoni M. Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. *Oncologist.* 2014 Dec;19(12):1276-83. doi: 10.1634/theoncologist.2014-0174. Epub 2014 Oct 23. PubMed PMID: 25342315; PubMed Central PMCID: PMC4257743.
154. Farolfi A, Carretta E, Luna CD, Ragazzini A, Gentili N, Casadei C, Barone D, Minguzzi M, Amadori D, Nanni O, Gavelli G. Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients? *BMC Cancer.* 2014 Oct 31;14:792. doi: 10.1186/1471-2407-14-792. PubMed PMID: 25361734; PubMed Central PMCID: PMC4223747.
155. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S,

Mucciarini C, Lorusso V, Ragazzini A, Frassineti GL, Amadori D. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. *Ann Oncol.* 2015 Mar 3. pii: mdv130. [Epub ahead of print] PubMed PMID: 25735317.

Libri o capitoli di libri

D. Amadori, C. Milandri, A. Volpi, O. Nanni. Medical Management of Neuroendocrine Tumors. In *Progress in Anti-Cancer chemotherapy*. Vol II. Edited by G. N. Hortobagay D. Khayat. Blackwell Science Inc. 1999.

M. Maltoni, O. Nanni, E. Scarpi, M. Pirovano and D. Amadori. Model for estimation of survival in patients with far-advanced cancer. In *Topics in Palliative Care*, 4 Oxford University Press, 2000

R. Ridolfi, O. Nanni. Dieta e cancro. Aspetti di prevenzione primaria del tratto gastroenterico. In *Prevenzione è vivere*. Lega Italiana per la Lotta contro i Tumori, Forlì 2001.

O. Nanni, L. Mariani. Fasi della sperimentazione clinica. In *Sperimentazione clinica in Oncologia: metodologia, strutture e risorse*. Poletto editore, 2004.

O. Nanni. Biostatistico. In *Sperimentazione clinica in Oncologia: metodologia, strutture e risorse*. Poletto editore, 2004.

La Commissione di Ricerca della Società Italiana di Cure Palliative (...O. Nanni...). *La ricerca in Cure Palliative: la normativa vigente per le sperimentazioni sui farmaci*. Società Italiana di Cure Palliative, 2006.

O. Nanni. Monitoraggio casistica clinica . In *Informatizzazione in Oncologia* . Poletto editore, 2008